ArriVent BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVBP Nasdaq 2836 arrivent.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ArriVent BioPharma, Inc.

Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference - Nov 2nd, 2026 3:00 pm
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study - Oct 26th, 2026 10:02 pm
ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone? - Oct 26th, 2026 7:08 pm
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 - Oct 25th, 2026 7:00 am
Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe - Oct 24th, 2026 6:14 am
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 - Oct 23rd, 2026 2:00 pm
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer - Oct 19th, 2026 6:01 am
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 - Oct 12th, 2026 2:01 pm
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails - Oct 7th, 2026 11:38 pm
ArriVent’s stock plummets on Phase III NSCLC trial failure - Oct 7th, 2026 8:50 am
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low - Oct 6th, 2026 12:09 pm
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’ - Oct 6th, 2026 11:50 am
ArriVent collapses on disappointing lung cancer data - Oct 6th, 2026 10:12 am
Why This Biotech Stock Is Having Its Worst Day Ever - Oct 6th, 2026 9:53 am
ArriVent stock tumbles 60% after trial misses primary endpoint - Oct 6th, 2026 7:12 am
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC - Oct 6th, 2026 6:00 am
ArriVent BioPharma Reports Second Quarter 2026 Financial Results - Aug 12th, 2026 2:01 pm
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight - Jun 15th, 2026 10:31 am
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight - Jun 1st, 2026 6:31 am
ArriVent BioPharma Reports First Quarter 2026 Financial Results - May 11th, 2026 2:01 pm